370 related articles for article (PubMed ID: 28073841)
1. Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.
Katsha A; Wang L; Arras J; Omar OM; Ecsedy J; Belkhiri A; El-Rifai W
Clin Cancer Res; 2017 Jul; 23(14):3756-3768. PubMed ID: 28073841
[No Abstract] [Full Text] [Related]
2. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.
Wang L; Arras J; Katsha A; Hamdan S; Belkhiri A; Ecsedy J; El-Rifai W
Mol Oncol; 2017 Aug; 11(8):981-995. PubMed ID: 28417568
[TBL] [Abstract][Full Text] [Related]
3. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
4. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of AURKA Reduces Proliferation and Survival of Gastrointestinal Cancer Cells With Activated KRAS by Preventing Activation of RPS6KB1.
Wang-Bishop L; Chen Z; Gomaa A; Lockhart AC; Salaria S; Wang J; Lewis KB; Ecsedy J; Washington K; Beauchamp RD; El-Rifai W
Gastroenterology; 2019 Feb; 156(3):662-675.e7. PubMed ID: 30342037
[TBL] [Abstract][Full Text] [Related]
6. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
7. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
[TBL] [Abstract][Full Text] [Related]
8. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma.
Demosthenous C; Han JJ; Stenson MJ; Maurer MJ; Wellik LE; Link B; Hege K; Dogan A; Sotomayor E; Witzig T; Gupta M
Oncotarget; 2015 Apr; 6(11):9488-501. PubMed ID: 25839159
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
10. Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V; Borakove M; Feng Y; Wuest WM; Koval AB; Nikonova AS; Serebriiskii I; Chernoff J; Borges VF; Golemis EA; Shagisultanova E
Breast Cancer Res Treat; 2019 Sep; 177(2):369-382. PubMed ID: 31254157
[TBL] [Abstract][Full Text] [Related]
11. HDM2 regulation by AURKA promotes cell survival in gastric cancer.
Sehdev V; Katsha A; Arras J; Peng D; Soutto M; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
Clin Cancer Res; 2014 Jan; 20(1):76-86. PubMed ID: 24240108
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
14. Cinobufagin Triggers Defects in Spindle Formation and Cap-Dependent Translation in Liver Cancer Cells by Inhibiting the AURKA-mTOR-eIF4E Axis.
Jin X; Wang J; Zou S; Xu R; Cao J; Zhang Y; Guo J; Wen X; Deng S; Zheng Y; Zhu Y; Wang F; Xu Z
Am J Chin Med; 2020; 48(3):651-678. PubMed ID: 32349518
[TBL] [Abstract][Full Text] [Related]
15. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.
Kuo SH; Hsu CH; Chen LT; Lu YS; Lin CH; Yeh PY; Jeng HJ; Gao M; Yeh KH; Cheng AL
Eur J Cancer; 2011 May; 47(8):1244-57. PubMed ID: 21334199
[TBL] [Abstract][Full Text] [Related]
16. ID1 overexpression promotes HCC progression by amplifying the AURKA/Myc signaling pathway.
Wu M; Zhou Y; Fei C; Chen T; Yin X; Zhang L; Ren Z
Int J Oncol; 2020 Sep; 57(3):845-857. PubMed ID: 32705157
[TBL] [Abstract][Full Text] [Related]
17. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
[TBL] [Abstract][Full Text] [Related]
18. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Long Half-Life AURKA Inhibitor to Treat MYC-Amplified Solid Tumors as a Monotherapy and in Combination with Everolimus.
Chang CP; Yeh TK; Chen CT; Wang WP; Chen YT; Tsai CH; Chen YF; Ke YY; Wang JY; Chen CP; Hsieh TC; Wu MH; Huang CL; Chen YP; Zhuang H; Chi YH
Mol Cancer Ther; 2024 Jun; 23(6):766-779. PubMed ID: 38592383
[TBL] [Abstract][Full Text] [Related]
20. A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer.
Dauch D; Rudalska R; Cossa G; Nault JC; Kang TW; Wuestefeld T; Hohmeyer A; Imbeaud S; Yevsa T; Hoenicke L; Pantsar T; Bozko P; Malek NP; Longerich T; Laufer S; Poso A; Zucman-Rossi J; Eilers M; Zender L
Nat Med; 2016 Jul; 22(7):744-53. PubMed ID: 27213815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
